Transcript John Ridden Blueberry Therapeutics

Dr John Ridden CEO and Co-Founder
26th June 2014
Building a bioscience
business in Cheshire
Blueberry - The company
• A small drug discovery and development company
• Projects through to clinical proof-of-concept, then license on for
further development
• Portfolio based on the innovative use of nanotechnology to
reformulate drugs and create NMEs
• Inflammation and infection focussed
• Current area of interest is dermatology
Building a bioscience business in Cheshire
Blueberry Therapeutics
Blueberry - The company
•
•
•
•
•
•
Based here at BioHub
120m2 lab space
30m2 office space
Fully Equipped
6 Staff
Bioscience and clinical
Building a bioscience business in Cheshire
Blueberry Therapeutics
Blueberry technology
Nanocin™
• Nanoparticle based delivery platform
• Massively enhances drug delivery into cells and tissues
Building a bioscience business in Cheshire
Blueberry Therapeutics
Blueberry technology
Nanocintm - enhanced topical delivery platform
•
•
•
•
•
•
Nanoparticles <20nm in diameter
First synthesised >80 years ago
>30 years of safe clinical use
Stable at room temperature for up to 5 years
Well tolerated in the eye, ear, skin, gut and lung.
Massively enhances drug delivery into cells and tissue.
–
–
–
–
–
–
Protein
Peptide,
DNA
RNA
Natural products
Small molecules
Building a bioscience business in Cheshire
Blueberry Therapeutics
Blueberry technology
Nanocintm technology - a clinically safe polymer
•
•
Already used in a range of over the counter and off the shelf human
healthcare products
Always as a biocide
Products containing Nanocin include; inter-operative irrigation, pre- and post-surgery skin and mucous membrane disinfection,
post-operative dressings, surgical and non-surgical wound dressings, surgical bath/hydrotherapy, chronic wounds like diabetic
foot ulcer and burn wound management, routine antisepsis during minor incisions, catheterization, ‘scopy, first aid, surface
disinfection, and linen disinfection
Eye drops
Wound dressing
Building a bioscience business in Cheshire
Wound care
Blueberry Therapeutics
Hand wash
Contact lens
The Blueberry Portfolio 2014
Preclinical
CTA/IND
Clinical
Launch
Onychomycosis
BB0305
Small molecule
2018
Tinea Pedis
BB2603
Small molecule
2016
Inflammatory bowel
disease BB0109
Peptide therapeutic
Atopic dermatitis
BB2702
Peptide therapeutic
MARKET
Drug resistant bacterial
infection BB5000
Peptide aptamer
Skin care
BB2300
Topical biologic
2015
Acne treatment
BB2312
Topical biologic
2017
Building a bioscience business in Cheshire
Blueberry Therapeutics
Building a bioscience business isn’t easy……
Building a bioscience business in Cheshire
Blueberry Therapeutics
The road ahead…
Building a bioscience business in Cheshire
Blueberry Therapeutics
…..requires careful navigation
Building a bioscience business in Cheshire
Blueberry Therapeutics
It’s about taking calculated risks
Building a bioscience business in Cheshire
Blueberry Therapeutics
With a solid team
We operate using a contemporary business model
•
•
•
•
Blueberry staff
Scientific and clinical advisory board
Partners
Collaborators
Building a bioscience business in Cheshire
Blueberry Therapeutics
The Blueberry management team and advisors
•
•
Blueberry have recruited an experienced advisory board ‘THE SCAB’
Working alongside our small but experienced team
Team Member
Biography
Dr Dave Cook (AstraZeneca)
Drug discovery, safety and inflammation
Dr Liam Good (RVC)
Nanopolymers and Bacteriology
Dr Maria Marlowe (Nottingham Bimolecular Centre)
Nanopolymer formulations
Dr Alex O’Neill (Leeds University)
Bacterial resistance mechanisms
Dr Wal Ward
Enzymology
Dr Sudax Murdan (UCL)
Fungal Infections
Dr Mike Davies
Drug Development
Building a bioscience business in Cheshire
Blueberry Therapeutics
Blueberry partners
Weightmans
Appleyard Lees
PITCH&CO
Blueberry
Therapeutics
Gary Burns
Biocity/Biohub
UKTI
Bionow
Building a bioscience business in Cheshire
Technology
Strategy Board
Blueberry Therapeutics
Blueberry collaborators
Leeds
University
Public Health
England
Manchester
University
Newcastle
University
Liverpool
University
Blueberry
Therapeutics
RVC
UCL
Pharma
SME
Building a bioscience business in Cheshire
Blueberry Therapeutics
Sheffield
University
Protecting intellectual property
Blueberry Patent & Intellectual Property Overview
Lead compound IP assigned from AstraZeneca to Blueberry Therapeutics in return for 1st right to
negotiate at PoC.

Candidate anti-inflammatory compounds in patent application phase


Exclusive license to an industry leading, clinically safe nanopolymer based delivery system
Patent applications for biologic approach to Bacterial Multi Drug Resistance

Patent application for fungal infection treatment


Exclusive license to 2 peptide aptamer screening platforms
Building a bioscience business in Cheshire
Blueberry Therapeutics
And finally…
After 3 years of being the leader of a Biotech business
“Experience
is something you don’t get until just after you need it!”
Building a bioscience business in Cheshire
Blueberry Therapeutics
Thank you
Dr John Ridden
Co-Founder / CEO
Tel: +44 77 94 569404
[email protected]